Spherix Incorporated was launched in 1967 as a scientific research company.
Today Spherix presently offers a diversified commercialization platform for protected technologies.
Spherix is committed to advancing innovation by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. Through its recently announced acquisition of over a hundred patents from Rockstar Consortium Inc and its previously announced acquisition of several hundred patents issued to Harris Corporation, Spherix intends to expand its activities in wireless communications and telecommunication sectors including antenna technology, Wi-Fi, base station functionality, and cellular. Spherix recently announced a second settlement and license agreement under the CompuFill patents, which were acquired in September 2013, that provides further validation of the company’s capabilities to drive value from its ever growing IP portfolio.
Spherix seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents. Spherix is traded on the NASDAQ under the ticker symbol SPEX.
Book Value: $10,000,000
Market Cap: $4,000,000
Float: ~2,600,000 shares I/O
Two years ago, Spherix invested approximately $700,000.00 in Hoth Therapeutics (NASDAQ: HOTH), a company with a focus on the development of drugs for Eczema. Today, Hoth Therapeutics trades with a market cap of around $50 million, about $10 million worth of the company is owned by Spherix.
$500,000 Dividend – October 21, 2019 is the record date for a dividend distribution. If you are a shareholder of record of SPEX at 5 p.m. Eastern Standard on that date, you will receive one share of Hoth common stock for every 29 shares of SPEX common stock you own. Spherix will not distribute fractional shares of Hoth common stock, and any fractional shares will be rounded down to the nearest whole share.
On September 9, 2019, SPEX announced approval by shareholders to acquire assets from CBM BioPharma, Inc. (CBM). Upon the closing of the asset acquisition, Spherix will acquire anticancer drugs that provide shareholders access to billion-dollar oncology markets. CBM is currently in the process of developing two treatment candidates to be acquired by Spherix:
KPC-34 – Under early development for acute myeloid leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), KPC-34 has shown early promise. Currently, Gemcitabine and Cytarabine are at the epicenter of treatment of AML and ALL. When compared to Cytarabine, KPC-34 has shown promise as a superior option. The global acute myeloid leukemia (AML) market is expected to reach $2.2 billion by 2025 growing at CAGR 19.6% over the forecast period. The global ALL market is expected to reach $3.5 billion by 2026 at 5.3% CAGR.
DHA-dFdC – DHA-dFdC is currently under development as a new drug for pancreatic cancer. Current treatment options include surgery, radiation therapy and chemotherapy, all of which are known to extend survival and relieve symptoms. Unfortunately, these treatments seldom result in a cured patient. Moreover, surgical tumor removal is only possible in under 20% of the patient population. All in all, there is a large medical need for positive therapies in this space. Positive preclinical study results suggest that DHA-dFdC is effective in inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. The pancreatic cancer market size was $2.41 billion in 2018 and estimated to grow at 7.54% CAGR, to reach $3.47 billion by 2023.
SPEX will pay about $7 million in stock, plus cash, for the acquisition of the pharmaceutical assets. However, there’s a caveat. Due to the fact that Spherix owns 20% of CBM, if and when CBM decides to sell shares associated with this deal, about 20% of the proceeds, or little more than $1 million, would come directly back to Spherix. That’s important as it means that a large portion of this deal will be completely self-funded.
Anthony Hayes, President, Chief Executive Officer, and Director
Anthony C. Hayes is an attorney and former partner of Nelson Mullins Riley & Scarborough LLP, an AMLaw 100 firm. Mr. Hayes has successfully monetized patents through a wide variety of monetization methods, including price arbitrage and litigation licensing brought against companies such as Cisco, Broadcom, Nokia, Ericsson, Tellabs, and Alcatel-Lucent. Mr. Hayes has received national recognition during his legal career, including: Special recognition by President George W. Bush, American Board of Trial Advocates Young Lawyer of the Year; and City of Columbia “20 Under 40.” Mr. Hayes earned a Juris Doctor from Tulane University School of Law in 1995 and his B.A. in Economics from Mary Washington College in Fredericksburg, Virginia in 1990.
Darrell Dotson, Licensing & Litigation
Mr. Dotson attended Texas A&M University in College Station, Texas and received a B.S. in Biology in 1988 and a second B.S. Degree in Zoology in 1989. After graduating from college, he attended The University of Texas Health/Science Center Graduate School of Biomedical Sciences in Houston, Texas, where he received his Ph.D. in Biochemistry and Molecular Biology in 1994. After graduate school, he attended University of Houston Law Center where he earned a J.D. in 1997.He is licensed to practice in all state courts in Texas and before the United States Patent and Trademark Office. He is also licensed in the United States District Courts for the Eastern and Southern Districts of Texas. For the past 13 years, Darrell has specialized in intellectual property litigation, including analysis of the infringement, validity and enforceability of patents.
Spherix offers our shareholders opportunities to benefit from many “shots on goal” offering results from manifold investments across a broad range of industries – this portfolio diversification approach permits valuing our overall company from the multitude of investments to be made by our portfolio managers acquiring interests in diverse and disparate potential income streams.
For our shareholders:
>> We believe Spherix is an opportunity to participate in the growing patent monetization sector with a single investment that provides a diversified interest in numerous portfolios with a multitude of cash flow potentials.
>> Patent monetization is uncorrelated to any known market trends and provides diversification from traditional cyclical investments.
>> Patent monetization is an unregulated industry sector.
>> We support innovation and help to foster and grow the next generation of innovators who are leading the country’s technology revolution.
>> We are on the leading edge of a developing market trend based on the law and constitution that is launching the largest transfer of technology in history.